PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
From:
Clin Lymphoma Myeloma Leuk. Author manuscript; available in PMC 2013 July 29.
Published in final edited form as:
Clin Lymphoma Myeloma Leuk. 2010 June; 10(3): 205–210.
doi: 10.3816/CLML.2010.n.032

Table 2

Dose Schedules of Therapy with Hypomethylating Agents

Dose ScheduleNumber of Patients
Azacitidine
 Subcutaneous: 75 mg/m2 per day for 7 days repeated every 4 weeks10
 Intravenous: 75 mg/m2 per day for 7 days repeated every 4 weeks1
Decitabine
 Intravenous: 20 mg/m2 per day over 1 hour for 5 days every 4 weeks18
 Intravenous: 15 mg/m2 per day over 1 hour for 5 days every 4 weeks4
 Intravenous: 10 mg/m2 per day over 1 hour for 5 days every 4 weeks2
 Intravenous: 10 mg/m2 per day over 1 hour for 10 days every 4 weeks1

Data were available for 36 patients.